A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT ID: NCT01009463
Last Updated: 2017-11-09
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1626 participants
INTERVENTIONAL
2009-09-25
2011-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FF/GW642444 Inhalation Powder 100/25 mcg QD
Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
FF/GW642444 Inhalation Powder
Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) delivered within one dry powder inhaler (DPI) device for COPD
FF/GW642444 Inhalation Powder 200/25 mcg QD
Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
FF/GW642444 Inhalation Powder
Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) delivered within one dry powder inhaler (DPI) device for COPD
FF/GW642444 Inhalation Powder 50mcg/25mcg QD
Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
FF/GW642444 Inhalation Powder
Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) delivered within one dry powder inhaler (DPI) device for COPD
GW642444 25mcg QD
Long Acting Beta Agonist(LABA)
GW642444 Inhalation Powder
Long Acting Beta Agonist(LABA) Inhalation Powder via DPI
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FF/GW642444 Inhalation Powder
Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) delivered within one dry powder inhaler (DPI) device for COPD
GW642444 Inhalation Powder
Long Acting Beta Agonist(LABA) Inhalation Powder via DPI
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Informed consent: Subjects must give their signed and dated written informed consent to participate.
* Gender: Male or female subjects A female is eligible to enter and participate in the study if she is of: Non-child bearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal or surgically sterile). Surgically sterile females are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal ligation. Post-menopausal females are defined as being amenorrhoeic for greater than 1 year with an appropriate clinical profile, e.g., age appropriate, history of vasomotor symptoms. However in questionable cases, a blood sample with FSH \> 40MIU/ml and estradiol \<40pg/ml (\<140 pmol/L) is confirmatory. OR
Child bearing potential, has a negative pregnancy test at screening, and agrees to one of the following acceptable contraceptive methods used consistently and correctly (i.e., in accordance with the approved product label and the instructions of the physician for the duration of the study - screening to follow-up contact):
* Complete abstinence from intercourse from screening until the Follow-Up Phone Contact; or
* Male partner is sterile (vasectomy with documentation of azoospermia) prior to female subject entry into the study, and this male partner is the sole partner for that subject; or
* Implants of levonorgestral inserted for at least 1 month prior to the study medication administration but not beyond the third successive year following insertion; or
* Injectable progestogen administered for at least 1 month prior to study medication administration and administered until the Follow-Up Phone Contact; or
* Oral contraceptive (combined or progestogen only) administered for at least one monthly cycle prior to study medication administration; or
* Double barrier method: condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent (foam/gel/film/cream/suppository); or
* An intrauterine device (IUD), inserted by a qualified physician, with published data showing that the highest expected failure rate is less than 1% per year; or
* Estrogenic vaginal ring; or
* Percutaneous contraceptive patches
* Age: ≥40 years of age at Screening (Visit 1)
* COPD diagnosis: Subjects with a clinical history of COPD in accordance with the following definition by the American Thoracic Society/European Respiratory Society \[Celli, 2004\]: COPD is a preventable and treatable disease characterized by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases, primarily caused by cigarette smoking. Although COPD affects the lungs, it also produces significant systemic consequences.
* Tobacco use: Subjects with a current or prior history of ≥10 pack-years of cigarette smoking at Screening (Visit 1). Former smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1. Note: Pipe and/or cigar use cannot be used to calculate pack-year history. Number of pack years = (number of cigarettes per day/20) x number of years smoked
* Severity of Disease:
* Subject with a measured post-albuterol/salbutamol FEV1/FVC ratio of ≤0.70 at Screening (Visit 1)
* Subjects with a measured post-albuterol/salbutamol FEV1 \<70% of predicted normal values calculated (via centralized vendor equipment) using NHANES III reference equations \[Hankinson, 1999\] at Screening (Visit 1). Post-bronchodilator spirometry will be performed approximately 10-15 minutes after the subject has self-administered 4 inhalations (i.e., total 400mcg) of albuterol/salbutamol via an MDI with a valved-holding chamber. The study provided central spirometry equipment will calculate the FEV1/FVC ratio and FEV1 percent predicted values.
* History of Exacerbations: A documented history (e.g., medical record verification) of at least one COPD exacerbation in the 12 months prior to Visit 1 that required either oral corticosteroids, antibiotics and/or hospitalization. Prior use of antibiotics alone does not qualify as an exacerbation history unless the use was associated with treatment of worsening symptoms of COPD, such as increased dyspnea, sputum volume, or sputum purulence (color). Subject verbal reports are not acceptable.
Exclusion Criteria
* Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study.
* Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history of asthma are eligible if they have a current diagnosis of COPD)
* α1-antitrypsin deficiency: Subjects with α1-antitrypsin deficiency as the underlying cause of COPD
* Other respiratory disorders: Subjects with active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases
* Lung resection: Subjects with lung volume reduction surgery within the 12 months prior to Screening (Visit 1)
* Chest X-ray (or CT scan): Subjects with a chest X-ray (or CT scan) that reveals evidence of clinically significant abnormalities not believed to be due to the presence of COPD. A chest X-ray must be taken at Screening (Visit 1) if a chest X-ray or CT scan is not available within 6 months prior to Visit 1. For sites in Germany, if a chest X-ray (or CT scan) is not available in the 6 months preceding Screening (Visit 1), the subject will not be eligible for the study.
* Risk Factors for Pneumonia: immune suppression (HIV, Lupus, etc) or other risk for pneumonia (e.g. neurological disorders affecting control of the upper airway, such as Parkinson's, Myasthenia Gravis, etc).
* A moderate and severe COPD exacerbation that has not resolved at least 14 days prior to Visit 1 and at least 30 days following the last dose of oral corticosteroids (if applicable).
* Pneumonia and/or moderate and severe COPD exacerbation at Visit 1 Note: Subjects who experience a pneumonia and/or exacerbation at Screening (Visit 1) must be not continue in the study, but may be re-screened at a later time provided the pneumonia and/or COPD exacerbation has resolved prior to the re-screening visit. At the Re-screening Visit, the chest x-ray should confirm resolution of pneumonia. The Re-screening Visit must be conducted at least ≥ 14 days following the resolution date of the exacerbation and/or pneumonia and at least 30 days following the last dose of oral corticosteroids (if applicable).
* Other diseases/abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular (i.e., pacemaker), neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or haematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
* Peptic Ulcer disease: Subjects with clinically significant peptic ulcer disease that is uncontrolled.
* Hypertension: Subjects with clinically significant hypertension that is uncontrolled.
* Cancer: Subjects with carcinoma that has not been in complete remission for at least 5 years. Carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma of the skin would not be excluded if the subject has been considered cured within 5 years since diagnosis.
* Drug/food allergy: Subjects with a history of hypersensitivity to any of the study medications (e.g., beta-agonists, corticosteroid) or components of the inhalation powder (e.g., lactose, magnesium stearate). In addition, subjects with a history of severe milk protein allergy that, in the opinion of the study physician, contraindicates the subject's participation will also be excluded.
* Drug/alcohol abuse: Subjects with a known or suspected history of alcohol or drug abuse within the last 2 years
* Medication prior to spirometry: Subjects who are medically unable to withhold their albuterol/salbutamol and/or their ipratropium for the 4-hour period required prior to spirometry testing at each study visit.
* Additional medication: Unable to stop using certain medications such as bronchodilators and corticosteroids for the protocol-specified times prior to Visit 1 (the Investigator will discuss the specific medications)
* Oxygen therapy: Subjects receiving treatment with long-term oxygen therapy (LTOT) or nocturnal oxygen therapy required for greater than 12 hours a day. Oxygen prn use (i.e., ≤12 hours per day) is not exclusionary.
* Sleep apnea: Subjects with clinically significant sleep apnea who require use of continuous positive airway pressure (CPAP) device or non-invasive positive pressure ventilation (NIPPV) device.
* Pulmonary rehabilitation: Subjects who have participated in the acute phase of a Pulmonary Rehabilitation Program within 4 weeks prior to Screening (Visit 1) or who will enter the acute phase of a Pulmonary Rehabilitation Program during the study. Subjects who are in the maintenance phase of a Pulmonary Rehabilitation Program are not excluded.
* Non-compliance: Subjects at risk of non-compliance, or unable to comply with the study procedures. Any infirmity, disability, or geographic location that would limit compliance for scheduled visits.
* Questionable validity of consent: Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study.
* Prior use of study medication/other investigational drugs: Subjects who have previously been randomized to treatment with GW642444 Inhalation Powder in the B2C111045 study, randomized to treatment in the HZC111348 study or have participated in the HZC112207, HZC102871, HZC102970, or HZC110946 studies. Subjects who have received an investigational drug within 30 days of entry into this study (Screening), or within 5 drug half-lives of the investigational drug, whichever is longer.
* Affiliation with investigator site: Study investigators, sub-investigators, study coordinators, employees of a participating investigator or immediate family members of the aforementioned are excluded from participating in this study.
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Jasper, Alabama, United States
GSK Investigational Site
Peoria, Arizona, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Scottsdale, Arizona, United States
GSK Investigational Site
Chula Vista, California, United States
GSK Investigational Site
Lincoln, California, United States
GSK Investigational Site
Long Beach, California, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Mission Viejo, California, United States
GSK Investigational Site
Palo Alto, California, United States
GSK Investigational Site
Poway, California, United States
GSK Investigational Site
Rancho Mirage, California, United States
GSK Investigational Site
Riverside, California, United States
GSK Investigational Site
Rolling Hills Estates, California, United States
GSK Investigational Site
Santa Monica, California, United States
GSK Investigational Site
Sepulveda, California, United States
GSK Investigational Site
Torrance, California, United States
GSK Investigational Site
Stamford, Connecticut, United States
GSK Investigational Site
Bay Pines, Florida, United States
GSK Investigational Site
Clearwater, Florida, United States
GSK Investigational Site
Clearwater, Florida, United States
GSK Investigational Site
Fort Myers, Florida, United States
GSK Investigational Site
Gainesville, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Orlando, Florida, United States
GSK Investigational Site
Ormond Beach, Florida, United States
GSK Investigational Site
Tamarac, Florida, United States
GSK Investigational Site
Winter Park, Florida, United States
GSK Investigational Site
Austell, Georgia, United States
GSK Investigational Site
Decatur, Georgia, United States
GSK Investigational Site
Lawrenceville, Georgia, United States
GSK Investigational Site
Belleville, Illinois, United States
GSK Investigational Site
River Forest, Illinois, United States
GSK Investigational Site
Avon, Indiana, United States
GSK Investigational Site
Lafayette, Indiana, United States
GSK Investigational Site
Muncie, Indiana, United States
GSK Investigational Site
Newburgh, Indiana, United States
GSK Investigational Site
Iowa City, Iowa, United States
GSK Investigational Site
Lenexa, Kansas, United States
GSK Investigational Site
Wichita, Kansas, United States
GSK Investigational Site
Munfordville, Kentucky, United States
GSK Investigational Site
Owensboro, Kentucky, United States
GSK Investigational Site
New Orleans, Louisiana, United States
GSK Investigational Site
Sunset, Louisiana, United States
GSK Investigational Site
Columbia, Maryland, United States
GSK Investigational Site
Saint Joseph, Michigan, United States
GSK Investigational Site
Southfield, Michigan, United States
GSK Investigational Site
Minneapolis, Minnesota, United States
GSK Investigational Site
Minneapolis, Minnesota, United States
GSK Investigational Site
Plymouth, Minnesota, United States
GSK Investigational Site
Saint Charles, Missouri, United States
GSK Investigational Site
Billings, Montana, United States
GSK Investigational Site
Lebanon, New Hampshire, United States
GSK Investigational Site
Ocean City, New Jersey, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
Elizabeth City, North Carolina, United States
GSK Investigational Site
Salisbury, North Carolina, United States
GSK Investigational Site
Dayton, Ohio, United States
GSK Investigational Site
Oklahoma City, Oklahoma, United States
GSK Investigational Site
Oklahoma City, Oklahoma, United States
GSK Investigational Site
Tulsa, Oklahoma, United States
GSK Investigational Site
Medford, Oregon, United States
GSK Investigational Site
Sellersville, Pennsylvania, United States
GSK Investigational Site
Johnston, Rhode Island, United States
GSK Investigational Site
Anderson, South Carolina, United States
GSK Investigational Site
Charleston, South Carolina, United States
GSK Investigational Site
Chester, South Carolina, United States
GSK Investigational Site
Gaffney, South Carolina, United States
GSK Investigational Site
Greenwood, South Carolina, United States
GSK Investigational Site
Greer, South Carolina, United States
GSK Investigational Site
Seneca, South Carolina, United States
GSK Investigational Site
Chattanooga, Tennessee, United States
GSK Investigational Site
New Tazewell, Tennessee, United States
GSK Investigational Site
Austin, Texas, United States
GSK Investigational Site
Boerne, Texas, United States
GSK Investigational Site
Fort Worth, Texas, United States
GSK Investigational Site
Kingwood, Texas, United States
GSK Investigational Site
Lake Jackson, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
Temple, Texas, United States
GSK Investigational Site
South Burlington, Vermont, United States
GSK Investigational Site
Abingdon, Virginia, United States
GSK Investigational Site
Charlottesville, Virginia, United States
GSK Investigational Site
Fredericksburg, Virginia, United States
GSK Investigational Site
Richmond, Virginia, United States
GSK Investigational Site
Virginia Beach, Virginia, United States
GSK Investigational Site
Lakewood, Washington, United States
GSK Investigational Site
Spokane, Washington, United States
GSK Investigational Site
Tacoma, Washington, United States
GSK Investigational Site
Wenatchee, Washington, United States
GSK Investigational Site
Cipolletti, Río Negro Province, Argentina
GSK Investigational Site
Buenos Aires, , Argentina
GSK Investigational Site
Buenos Aires, , Argentina
GSK Investigational Site
Buenos Aires, , Argentina
GSK Investigational Site
Buenos Aires, , Argentina
GSK Investigational Site
Mendoza, , Argentina
GSK Investigational Site
Garran, Australian Capital Territory, Australia
GSK Investigational Site
Cairns, Queensland, Australia
GSK Investigational Site
Kippa-Ring, Queensland, Australia
GSK Investigational Site
Daw Park, South Australia, Australia
GSK Investigational Site
Frankston, Victoria, Australia
GSK Investigational Site
Geelong, Victoria, Australia
GSK Investigational Site
Heidelberg, Victoria, Australia
GSK Investigational Site
Nedlands, Western Australia, Australia
GSK Investigational Site
Vancouver, British Columbia, Canada
GSK Investigational Site
St. John's, Newfoundland and Labrador, Canada
GSK Investigational Site
Burlington, Ontario, Canada
GSK Investigational Site
Corunna, Ontario, Canada
GSK Investigational Site
Greater Sudbury, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Temuco, Región de La Araucania, Chile
GSK Investigational Site
Valparaíso, Región de Valparaíso, Chile
GSK Investigational Site
Santiago, , Chile
GSK Investigational Site
Rakvere, , Estonia
GSK Investigational Site
Tallinn, , Estonia
GSK Investigational Site
Tallinn, , Estonia
GSK Investigational Site
Tartu, , Estonia
GSK Investigational Site
Geesthacht, Schleswig-Holstein, Germany
GSK Investigational Site
Berlin, , Germany
GSK Investigational Site
Berlin, , Germany
GSK Investigational Site
Berlin, , Germany
GSK Investigational Site
Cassano Murge (BA), Apulia, Italy
GSK Investigational Site
Eboli (SA), Campania, Italy
GSK Investigational Site
Telese Terme (BN), Campania, Italy
GSK Investigational Site
Ferrara, Emilia-Romagna, Italy
GSK Investigational Site
Rome, Lazio, Italy
GSK Investigational Site
Rome, Lazio, Italy
GSK Investigational Site
Genoa, Liguria, Italy
GSK Investigational Site
Milan, Lombardy, Italy
GSK Investigational Site
Tradate (VA), Lombardy, Italy
GSK Investigational Site
Torrette (AN), The Marches, Italy
GSK Investigational Site
Tijuana, Baja California Norte, Mexico
GSK Investigational Site
Guadalajara, Jalisco, Mexico
GSK Investigational Site
Zapopan, Jalisco, Mexico
GSK Investigational Site
Monterrey, Nuevo León, Mexico
GSK Investigational Site
Bunnik, , Netherlands
GSK Investigational Site
Enschede, , Netherlands
GSK Investigational Site
Etten-Leur, , Netherlands
GSK Investigational Site
Harderwijk, , Netherlands
GSK Investigational Site
Heerlen, , Netherlands
GSK Investigational Site
Helmond, , Netherlands
GSK Investigational Site
Nijverdal, , Netherlands
GSK Investigational Site
Rotterdam, , Netherlands
GSK Investigational Site
Sneek, , Netherlands
GSK Investigational Site
Spijkenisse, , Netherlands
GSK Investigational Site
Veldhoven, , Netherlands
GSK Investigational Site
Voerendaal, , Netherlands
GSK Investigational Site
Jesus Maria, Lima region, Peru
GSK Investigational Site
San Martín de Porres, Lima region, Peru
GSK Investigational Site
Lima, , Peru
GSK Investigational Site
Lima, , Peru
GSK Investigational Site
Dagupan, , Philippines
GSK Investigational Site
Quezon City, , Philippines
GSK Investigational Site
Quezon City, , Philippines
GSK Investigational Site
Quezon City, , Philippines
GSK Investigational Site
Cape Town, Gauteng, South Africa
GSK Investigational Site
Mueckelneck, Gauteng, South Africa
GSK Investigational Site
Boksburg North, , South Africa
GSK Investigational Site
Cape Town, , South Africa
GSK Investigational Site
Durban, , South Africa
GSK Investigational Site
Durban, , South Africa
GSK Investigational Site
Groenkloof, , South Africa
GSK Investigational Site
Lynnwood Manor, , South Africa
GSK Investigational Site
Lyttleton, , South Africa
GSK Investigational Site
Paarl, , South Africa
GSK Investigational Site
Panorama, , South Africa
GSK Investigational Site
Reiger Park, , South Africa
GSK Investigational Site
Somerset West, , South Africa
GSK Investigational Site
Witbank, , South Africa
GSK Investigational Site
Gothenburg, , Sweden
GSK Investigational Site
Gothenburg, , Sweden
GSK Investigational Site
Höllviken, , Sweden
GSK Investigational Site
Kil, , Sweden
GSK Investigational Site
Örebro, , Sweden
GSK Investigational Site
High Heaton, Newcastle Upon Tyne, Tyne & Wear, United Kingdom
GSK Investigational Site
Doncaster, , United Kingdom
GSK Investigational Site
Liverpool, , United Kingdom
GSK Investigational Site
London, , United Kingdom
GSK Investigational Site
London, , United Kingdom
GSK Investigational Site
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Sanford L, Lettis S, Crim C, Calverley PM. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013 May;1(3):210-23. doi: 10.1016/S2213-2600(13)70040-7. Epub 2013 Apr 12.
Largajolli A, Beerahee M, Yang S. Bayesian approach to investigate a two-state mixed model of COPD exacerbations. J Pharmacokinet Pharmacodyn. 2019 Aug;46(4):371-384. doi: 10.1007/s10928-019-09643-6. Epub 2019 Jun 13.
Hinds DR, DiSantostefano RL, Le HV, Pascoe S. Identification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysis. BMJ Open. 2016 Jun 1;6(6):e010099. doi: 10.1136/bmjopen-2015-010099.
Crim C, Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Lettis S, Calverley PM. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc. 2015 Jan;12(1):27-34. doi: 10.1513/AnnalsATS.201409-413OC.
Svedsater H, Dale P, Garrill K, Walker R, Woepse MW. Qualitative assessment of attributes and ease of use of the ELLIPTA dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med. 2013 Dec 7;13:72. doi: 10.1186/1471-2466-13-72.
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: Informed Consent Form
View DocumentDocument Type: Statistical Analysis Plan
View DocumentDocument Type: Dataset Specification
View DocumentDocument Type: Clinical Study Report
View DocumentDocument Type: Study Protocol
View DocumentDocument Type: Individual Participant Data Set
View DocumentDocument Type: Annotated Case Report Form
View DocumentRelated Links
Access external resources that provide additional context or updates about the study.
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
102871
Identifier Type: -
Identifier Source: org_study_id